DOCSLIB.ORG

Wilms' Tumor Gene 1 in Different Types of Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wilms' Tumor Gene 1 in Different Types of Cancer UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New Series No.1717 ISSN 0346-6612 ISBN 978-91-7601-263-5 Wilms’ tumor gene 1 in different types of cancer Xingru Li Department of Medical Biosciences, Clinical Chemistry Umeå University, Sweden Umeå 2015 Copyright © 2015 Xingru Li ISBN: 978-91-7601-263-5 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden, 2015 To my family Table of Contents Abstract .......................................................................................................... 1 Original Articles ............................................................................................. 2 Abbreviations ................................................................................................. 3 Introduction .................................................................................................... 4 WT1 (Wilms’ tumor gene 1) ...................................................................... 4 Structure of WT1 ..................................................................................... 4 WT1, the transcription factor ................................................................. 5 WT1 and its interacting partners ............................................................ 5 WT1 function .......................................................................................... 8 The tumor suppressor ........................................................................ 8 An oncogene ...................................................................................... 8 Mutations and single nucleotide polymorphisms (SNPs) in WT1 ............ 10 WT1 mutations ...................................................................................... 10 SNPs in WT1 ......................................................................................... 11 Methylation of WT1 ................................................................................. 11 DNA methylation .................................................................................. 11 WT1 methylation in different types of cancer ....................................... 12 Different methods for detecting DNA methylation ............................... 13 Genome-scale DNA methylation analysis methods ......................... 14 Locus-specific DNA methylation detection methods ....................... 14 Clinical relevance of the WT1 gene.......................................................... 14 WT1 in acute leukemia ......................................................................... 14 WT1 in RCC .......................................................................................... 15 WT1 in squamous cell carcinoma of the head and neck (SCCHN) ...... 15 p53/p63 in SCCHN ............................................................................... 16 Aims of the thesis ......................................................................................... 17 Materials and methods .................................................................................. 18 Tumor samples and cell culture (paper I - IV) ......................................... 18 RNA extraction and cDNA preparation (papers I - IV) ........................... 19 WT1 RNA Expression with RQ-PCR (papers I - IV) ............................... 19 Genomic DNA Preparation (papers II and III) ......................................... 19 Sequencing Analysis of the WT1 Genes (paper II) .................................. 19 Pyrosequencing (paper III) ....................................................................... 20 Transient transfection (paper IV) ............................................................. 20 siRNA transfection ................................................................................ 20 WT1D plasmid transfections ................................................................ 20 MTT assay (paper IV) .............................................................................. 21 Western blot (paper IV) ........................................................................... 21 Chromatin immunoprecipitation (ChIP)/PCR analysis (paper IV) .......... 21 Genome-wide gene expression array (paper IV) ...................................... 22 Genome-wide DNA methylation array (paper III) ................................... 22 Protein co-immunoprecipitation (paper IV) ............................................. 23 Statistical Analysis ................................................................................... 23 Results and Discussion ................................................................................. 24 Paper I ...................................................................................................... 24 Paper II ..................................................................................................... 25 Paper III .................................................................................................... 27 Paper IV ................................................................................................... 31 Conclusions .................................................................................................. 36 Acknowledgements ...................................................................................... 37 References .................................................................................................... 40 Abstract The Wilms’ tumor gene 1 (WT1) was first reported as a tumor suppressor gene in Wilms’ tumor. However, later studies have shown the oncogenic properties of WT1 in a variety of tumors. It was recently proposed that WT1 was a chameleon gene, due to its dual functions in tumorigenesis. We aimed to investigate the clinical significance of WT1 as biomarker in acute myeloid leukemia (AML) and clear cell renal cell carcinoma (ccRCC) and to elucidate the function of WT1 as an oncogene in squamous cell carcinoma of head and neck (SCCHN). In AML, it was suggested that WT1 expression was an applicable marker of minimal residual disease (MRD). In adult patients with AML, we found a good correlation between WT1 expression levels normalized to two control genes, -actin and ABL. Outcome could be predicted by a reduction in WT1 expression in bone marrow (≥ 1-log) detected less than 1 month after diagnosis, when -actin was used as control. Also, irrespective of the control gene used, outcome could be predicted by a reduction in WT1 expression in peripheral blood (≥ 2-log) detected between 1 and 6 months after treatment initiation. Previous studies in RCC demonstrated that WT1 acted as a tumor suppressor. Thus, we tested whether single nucleotide polymorphisms (SNPs) or mutations in WT1 might be associated with WT1 expression and clinical outcome in patients with ccRCC. We performed sequencing analysis on 10 exons of the WT1 gene in a total of 182 patient samples, and we identified six different SNPs in the WT1 gene. We found that at least one or two copies of the minor allele were present in 61% of ccRCC tumor samples. However, no correlation was observed between WT1 SNP genotypes and RNA expression levels. Moreover, none of the previously reported WT1 mutations were found in ccRCC. Nevertheless, we found that a favorable outcome was associated the homozygous minor allele for WT1 SNP. We then further investigated whether WT1 methylation was related to WT1 expression and its clinical significance. Methylation array and pyrosequencing analyses showed that the WT1 promoter region CpG site, cg22975913, was the most frequently hypermethylated CpG site. We found a trend that showed nearly significant correlation between WT1 mRNA levels and hypermethylation in the 5’-untranslated region. Hypermethylation in the WT1 CpG site, cg22975913, was found to be associated with patient age and a worse prognosis. One previous study reported that WT1 was overexpressed in SCCHN. That finding suggested that WT1 might play a role in oncogenesis. We found that both WT1 and p63 could promote cell proliferation. A positive correlation between WT1 and p63 expression was observed, and we identified p63 as a WT1 target gene. Furthermore, several known WT1 and p63 target genes were affected by knocking down WT1. Also, co-immunoprecipitation analyses demonstrated a protein interaction between WT1 and p53. In summary, WT1 gene expression can provide useful information for MRD detection during treatment of patients with AML. In RCC, our results suggested that the prognostic impact of WT1 SNPs was limited to the subgroup of patients that were homozygous for the minor allele, and that WT1 promoter hypermethylation could be used as a prognostic biomarker. In SCCHN, WT1 and p63 acted as oncogenes by affecting multiple genes involved in cancer cell growth. 1 Original Articles This thesis is based on the following papers and manuscripts: I. Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, Li A. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol. 2012 Dec; 21(4):225-33. II. Li X, Wang S, Sitaram RT, Andersson C, Ljungberg B, Li A. Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma. PLoS One. 8(3):e58396. doi: 10.1371/journal.pone.0058396. 2013 III. Li X, Evelönn E A, Wang S, Sitaram RT, Landfors M, Ottosson S, Andersson C, Nilsson S, Ljungberg B, Li A. Prognostic significance of hypermethylation in the promoter region of the Wilms’ tumour gene 1 in clear cell renal cell carcinoma. Manuscript. IV. Li X, Ottosson
Load more

Recommended publications
  • Wt1) – an Effector in Leukemogenesis?
    WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Vidovic, Karina 2010 Link to publication Citation for published version (APA): Vidovic, K. (2010). WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 07. Oct. 2021 Division of Hematology and Transfusion Medicine Lund University, Lund, Sweden WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Karina Vidovic Thesis 2010 Contact adress Karina Vidovic Division of Hematology and Transfusion Medicine BMC, C14 Klinikgatan 28 SE- 221 84 Lund Sweden Phone +46 46 222 07 30 e-mail: [email protected] ISBN 978-91-86443-99-3 ! Karina Vidovic Printed by Media-Tryck, Lund, Sweden 2 ”The journey of a thousand miles begins with one step” Lao Tzu (Chinese taoist), 600-531 BC 3 4 LIST OF PAPERS This thesis is based on the following papers, referred to in the text by their Roman numerals I.
    [Show full text]
  • An Integrated Genome Screen Identifies the Wnt Signaling Pathway As a Major Target of WT1
    An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1 Marianne K.-H. Kima,b, Thomas J. McGarryc, Pilib O´ Broind, Jared M. Flatowb, Aaron A.-J. Goldend, and Jonathan D. Lichta,b,1 aDivision of Hematology/Oncology and cFeinberg Cardiovascular Research Institute, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; bRobert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611; and dDepartment of Information Technology, National University of Ireland, Galway, Republic of Ireland Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved May 18, 2009 (received for review February 12, 2009) WT1, a critical regulator of kidney development, is a tumor suppressor control. A first generation of in vitro cotransfection and DNA for nephroblastoma but in some contexts functions as an oncogene. binding assays have given way to more biologically relevant exper- A limited number of direct transcriptional targets of WT1 have been iments where manipulation of WT1 levels has been accompanied identified to explain its complex roles in tumorigenesis and organo- by examination of candidate or global gene expression. Classes of genesis. In this study we performed genome-wide screening for direct WT1 targets thus identified consist of inducers of differentiation, WT1 targets, using a combination of ChIP–ChIP and expression arrays. regulators of cell growth and modulators of cell death. WT1 target Promoter regions bound by WT1 were highly G-rich and resembled genes include CDKN1A (22), a negative regulator of the cell cycle; the sites for a number of other widely expressed transcription factors AREG (23), a facilitator of kidney differentiation; WNT4 (24), a such as SP1, MAZ, and ZNF219.
    [Show full text]
  • Cited2 Controls Left-Right Patterning and Heart Development Through a Nodal-Pitx2c Pathway
    ARTICLES Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway Simon D Bamforth1,6,Jose´ Braganc¸a1,6, Cassandra R Farthing1,6,Ju¨rgen E Schneider1, Carol Broadbent1, Anna C Michell1, Kieran Clarke2, Stefan Neubauer1, Dominic Norris3, Nigel A Brown4, Robert H Anderson5 & Shoumo Bhattacharya1 Malformations of the septum, outflow tract and aortic arch are the most common congenital cardiovascular defects and occur in mice lacking Cited2, a transcriptional coactivator of TFAP2. Here we show that Cited2–/– mice also develop laterality defects, including right isomerism, abnormal cardiac looping and hyposplenia, which are suppressed on a mixed http://www.nature.com/naturegenetics genetic background. Cited2–/– mice lack expression of the Nodal target genes Pitx2c, Nodal and Ebaf in the left lateral plate mesoderm, where they are required for establishing laterality and cardiovascular development. CITED2 and TFAP2 were detected at the Pitx2c promoter in embryonic hearts, and they activate Pitx2c transcription in transient transfection assays. We propose that an abnormal Nodal-Pitx2c pathway represents a unifying mechanism for the cardiovascular malformations observed in Cited2–/– mice, and that such malformations may be the sole manifestation of a laterality defect. Genetic, developmental and molecular studies over the past decade transcription factors by linking them to EP300 and CREBBP9,15,16. have identified a number of DNA-binding transcription factors that Mutations in Tcfap2a and TFAP2B (Char syndrome) result in cardiac have key roles in cardiac morphogenesis and in the pathogenesis of and aortic arch malformations17,18, suggesting that coactivation of common congenital heart defects1. The role of transcriptional coacti- TFAP2 by CITED2, EP300 and CREBBP is necessary for the normal vators, molecules that connect DNA-binding transcription factors to development of these structures9.
    [Show full text]
  • Structure and Evolution of Four POU Domain Genes Expressed in Mouse Brain (POU Bnain-/POU Brain-2/POU Brain4/POU Scip/Homeobox) YOSHINOBU HARA*, ALESSANDRA C
    Proc. Natl. Acad. Sci. USA Vol. 89, pp. 3280-3284, April 1992 Neurobiology Structure and evolution of four POU domain genes expressed in mouse brain (POU Bnain-/POU Brain-2/POU Brain4/POU Scip/homeobox) YOSHINOBU HARA*, ALESSANDRA C. ROVESCALLI, YONGSOK KIM, AND MARSHALL NIRENBERG Laboratory of Biochemical Genetics, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 Contributed by Marshall Nirenberg, January 6, 1992 ABSTRACT Four mouse POU domain genomic DNA acid sequences of the proteins are related to one another and clones-Brain-i, Brain-2, Brain-4, and Scip-and Bran-2 suggests that the genes originated by duplication of an cDNA, which are expressed in adult brain, were cloned and the ancestral class III POU domain gene.t coding and noncoding regions ofthe genes were sequenced. The amino acid sequences of the four PoU domains are highly conserved; sequences in other regions of the proteins also are MATERIALS AND METHODS conserved but to a lesser extent. The absence of introns from DNA Coming and Sequencing. Our objective was to clone the coding regions of the four POU domain genes and the POU domain genes expressed in mouse brain. Mixtures of similarity of amino acid sequences of the corresponding pro- oligodeoxynucleotides that correspond to highly conserved teins suggest that the coding region of the ancestral class HI amino acid sequences in POU domains were used as primers POU domain gene lacked introns and therefore may have for amplification ofadult mouse brain POU domain cDNA by originated by reverse transcription of a molecule of POU PCR, and the amplified DNA fragments were cloned.
    [Show full text]
  • BRN2 Is a Transcriptional Repressor of CDH13 (T-Cadherin)
    Laboratory Investigation (2012) 92, 1788–1800 & 2012 USCAP, Inc All rights reserved 0023-6837/12 $32.00 BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells Lisa Ellmann1, Manjunath B Joshi2,3, Therese J Resink2, Anja K Bosserhoff1 and Silke Kuphal1 T-cadherin (cadherin 13, H-cadherin, gene name CDH13) has been proposed to act as a tumor-suppressor gene as its expression is significantly diminished in several types of carcinomas, including melanomas. Allelic loss and promoter hypermethylation have been proposed as mechanisms for silencing of CDH13. However, they do not account for loss of T-cadherin expression in all carcinomas, and other genetic or epigenetic alterations can be presumed. The present study investigated transcriptional regulation of CDH13 in melanoma. Bioinformatical analysis pointed to the presence of known BRN2 (also known as POU3F2 and N-Oct-3)-binding motifs in the CDH13 promoter sequence. We found an inverse correlation between BRN2 and T-cadherin protein and transcript expression. Reporter gene analysis and electrophoretic mobility shift assays in melanoma cells demonstrated that CDH13 is a direct target of BRN2 and that BRN2 is a functional transcriptional repressor of CDH13 promoter activity. The regulatory binding element of BRN2 was located À 219 bp of the CDH13 promoter proximal to the start codon and was identified as 50-CATGCAAAA-30. Ectopic expression of BRN2 in BRN2-negative/T-cadherin-positive melanoma cells resulted in suppression of CDH13 promoter activity, whereas BRN2 knockdown in BRN2-positive/T-cadherin-negative melanoma cells resulted in re-expression of T-cadherin transcripts and protein.
    [Show full text]
  • POU Domain Family Values: Flexibility, Partnerships, and Developmental Codes
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW POU domain family values: flexibility, partnerships, and developmental codes Aimee K. Ryan and Michael G. Rosenfeld 1 Howard Hughes Medical Institute, Department and School of Medicine, University of California at San Diego, La Jolla, Califiornia 92093-0648 USA Transcription factors serve critical roles in the progres- primary focus of this review. Crystallization of the Oct-1 sive development of general body plan, organ commit- and Pit-1 POU domains on DNA and in vitro studies ment, and finally, specific cell types. It has been the hope examining the specificity of POU domain cofactor inter- of most developmental biologists that comparison of the actions suggest that the flexibility with which the POU biological roles of a series of individual members within domain recognizes DNA-binding sites is a critical com- a family will permit at least some predictive generaliza- ponent of its ability to regulate gene expression. The tions regarding the developmental events that are likely implications of these data with respect to the mecha- to be regulated by a particular class of transcription fac- nisms utilized by the POU domain family of transcrip- tors. Here, we present an overview of the developmental tion factors to control developmental events will also be functions of the family of transcription factors charac- discussed. terized by the POU DNA-binding motif afforded by re- cent in vivo studies. Conformation of the POU domain on DNA The POU domain family of transcription factors was defined following the observation that the products of High-affinity site-specific DNA binding by POU domain three mammalian genes, Pit-l, Oct-l, and Oct-2 and the transcription factors requires both the POU-specific do- protein encoded by the Caenorhabditis elegans gene main and the POU homeodomain (Sturm and Herr 1988; unc-86 shared a region of homology, known as the POU Ingraham et al.
    [Show full text]
  • Significance of Wilms' Tumor Gene 1 As a Biomarker in Acute Leukemia and Solid Tumors
    UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New Series No. 1799 ISSN 0346-6612 ISBN 978-91-7601-458-5 Significance of Wilms’ Tumor Gene 1 as a Biomarker in Acute Leukemia and Solid Tumors Charlotta Andersson Department of Medical Biosciences, Clinical Chemistry and Pathology Umeå University, Sweden Umeå 2016 Copyright © 2016 Charlotta Andersson ISBN: 978-91-7601-458-5 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden, 2016 In memory of Aihong Li Table of Contents Table of Contents i Abstract iii Abbreviations iv List of Papers v Introduction 1 WT1 structure 1 WT1 target genes 3 WT1 protein partners 5 WT1 in normal and abnormal development 5 Hematopoiesis and WT1 7 WT1 as a tumor suppressor gene 7 WT1 as an oncogene or a chameleon gene 7 Acute leukemia (AL) and WT1 in AL 8 Renal cell carcinoma (RCC) and WT1 in RCC 13 Ovarian carcinoma (OC) and WT1 in OC 15 Aims of the Thesis 20 Materials and Methods 21 Patients and tissue samples (Papers I-IV) 21 Classification and risk group stratification in AL (Papers I and IV) 22 ccRCC grade and stage (Paper II) 22 OC classification, grade and stage (Paper III) 22 Genomic DNA preparation, RNA extraction and cDNA preparation (Papers I, II and IV) 23 Quantitative assessment of WT1 transcript expression with real-time quantitative PCR (RQ-PCR) (Papers I and II) 23 Sequencing analysis of the WT1 gene (Papers II and IV) 24 Immunohistochemistry (IHC) (Paper III) 24 Enzyme-linked immunosorbent assay (ELISA) (Paper III) 25 Statistical analysis 25 Results and Discussion 27 Paper I 27 Paper II 31 Paper III 35 Paper IV 38 Conclusions 42 Acknowledgments 44 References 47 i ii Abstract Wilms’ tumor gene 1 (WT1) is a zinc finger transcriptional regulator with crucial functions in embryonic development.
    [Show full text]
  • Brief Report
    BRIEF REPORT CITED2 mutations potentially cause idiopathic premature ovarian failure DORA JANETH FONSECA, DIEGO OJEDA, BESMA LAKHAL, RIM BRAHAM, STEFANIE EGGERS, ERIN TURBITT, STEFAN WHITE, SONIA GROVER, GARRY WARNE, MARGARET ZACHARIN, ^ ALEXANDRA NEVIN LAM, HANENE LANDOLSI, HATEM ELGHEZAL, ALI SAAD, CARLOS MARTIN RESTREPO, MARC FELLOUS, ANDREW SINCLAIR, PETER KOOPMAN, and PAUL LAISSUE BOGOTA, COLOMBIA; SOUSSE, TUNISIA; MELBOURNE AND BRISBANE, AUSTRALIA; AND PARIS, FRANCE Anomalies in gonadal development in a mouse knockout model of Cited2 have been recently described. In Cited2 2/2 female gonads, an ectopic cell migration was observed and the female program of sex determination was transiently delayed. We hypothesize that, in humans, this temporary inhibition of genes should be sufficient to provoke a developmental impairment of the female gonads, conducive to prema- ture ovarian failure (POF). To establish whether CITED2 mutations are a common cause of the disease, we performed a mutational analysis of this gene in a panel of patients with POF and in a group of control women with normal fertility. We amplified and di- rectly sequenced the complete open reading frame of CITED2 in 139 patients with POF and 290 controls. This study revealed 5 synonymous and 3 nonsynonymous vari- ants. Among these, 7 are novel. The nonsynonymous variant c.604C.A (p.Pro202Thr) was found uniquely in 1 woman from the POF group. In silico analysis of this mutation indicated a potential deleterious effect. We conclude that mutations in CITED2 may be involved
    [Show full text]
  • The Oct1 Homolog Nubbin Is a Repressor of NF-Κb-Dependent Immune Gene Expression That Increases the Tolerance to Gut Microbiota
    Dantoft et al. BMC Biology 2013, 11:99 http://www.biomedcentral.com/1741-7007/11/99 RESEARCH ARTICLE Open Access The Oct1 homolog Nubbin is a repressor of NF-κB-dependent immune gene expression that increases the tolerance to gut microbiota Widad Dantoft1, Monica M Davis1, Jessica M Lindvall2, Xiongzhuo Tang1, Hanna Uvell1,3, Anna Junell1, Anne Beskow1,4 and Ylva Engström1* Abstract Background: Innate immune responses are evolutionarily conserved processes that provide crucial protection against invading organisms. Gene activation by potent NF-κB transcription factors is essential both in mammals and Drosophila during infection and stress challenges. If not strictly controlled, this potent defense system can activate autoimmune and inflammatory stress reactions, with deleterious consequences for the organism. Negative regulation to prevent gene activation in healthy organisms, in the presence of the commensal gut flora, is however not well understood. Results: We show that the Drosophila homolog of mammalian Oct1/POU2F1 transcription factor, called Nubbin (Nub), is a repressor of NF-κB/Relish-driven antimicrobial peptide gene expression in flies. In nub1 mutants, which lack Nub-PD protein, excessive expression of antimicrobial peptide genes occurs in the absence of infection, leading to a significant reduction of the numbers of cultivatable gut commensal bacteria. This aberrant immune gene expression was effectively blocked by expression of Nub from a transgene. We have identified an upstream regulatory region, containing a cluster of octamer sites, which is required for repression of antimicrobial peptide gene expression in healthy flies. Chromatin immunoprecipitation experiments demonstrated that Nub binds to octamer-containing promoter fragments of several immune genes.
    [Show full text]
  • Action by CITED2 in the Nucleus B Κ
    Negative Feedback Regulation of NF-κB Action by CITED2 in the Nucleus Xiwen Lou, Shaogang Sun, Wei Chen, Yi Zhou, Yuefeng Huang, Xing Liu, Yufei Shan and Chen Wang This information is current as of September 29, 2021. J Immunol 2011; 186:539-548; Prepublished online 22 November 2010; doi: 10.4049/jimmunol.1001650 http://www.jimmunol.org/content/186/1/539 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/11/22/jimmunol.100165 Material 0.DC1 References This article cites 45 articles, 19 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/186/1/539.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Negative Feedback Regulation of NF-kB Action by CITED2 in the Nucleus Xiwen Lou, Shaogang Sun, Wei Chen, Yi Zhou, Yuefeng Huang, Xing Liu, Yufei Shan, and Chen Wang NF-kB is a family of important transcription factors that modulate immunity, development, inflammation, and cancer.
    [Show full text]
  • The POU-Domain Transcription Factor Oct- 6/POU3F1 As a Regulator of Cellular Response to Genotoxic Stress
    Article The POU-Domain Transcription Factor Oct- 6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress Cinzia Fionda 1,*,†, Danilo Di Bona 2,†, Andrea Kosta 1, Helena Stabile 1, Angela Santoni 1,3,4 and Marco Cippitelli 1,* 1 Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy; [email protected] (A.K.), [email protected] (H.S.); [email protected] (A.S.) 2 School and Chair of Allergology, Department of Emergencies and Organ Transplantation, University of Bari “Aldo Moro”, 70124 Bari, Italy; [email protected] 3 IRCCS, Neuromed, 86077 Pozzilli, Italy 4 Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00161 Rome, Italy * Correspondence: [email protected] (C.F.); [email protected] (M.C.); Tel.: +39-0649255152 (C.F. & M.C.); Fax: +39-0644340632 (C.F. & M.C.) † These authors equally contributed to this work. Received: 21 May 2019; Accepted: 6 June 2019; Published: 11 June 2019 Abstract: DNA damage and the generation of reactive oxygen species (ROS) are key mechanisms of apoptotic cell death by commonly used genotoxic drugs. However, the complex cellular response to these pharmacologic agents remains yet to be fully characterized. Several studies have described the role of transcription factor octamer-1 (Oct-1)/Pit-1, Oct-1/2, and Unc-86 shared domain class 2 homeobox 1 (POU2F1) in the regulation of the genes important for cellular response to genotoxic stress. Evaluating the possible involvement of other POU family transcription factors in these pathways, we revealed the inducible expression of Oct-6/POU3F1, a regulator of neural morphogenesis and epidermal differentiation, in cancer cells by genotoxic drugs.
    [Show full text]
  • Dysregulation of Meox2 Following Wt1 Mutation in Kidney Development and Wilms Tumorigenesis
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2011 DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS LaGina M. Nosavanh LaGina Merie Nosavanh Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation Nosavanh, LaGina M. and Nosavanh, LaGina Merie, "DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS" (2011). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 203. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/203 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS by LaGina Merie Nosavanh, B.S.
    [Show full text]